Breaking News

Silo Pharma Reaches Nasal Formulation Milestone for SPC-15

Formulation will be used in SPC-15’s novel protocol intended for treatment and prevention of anxiety, PTSD, and other stress related disorders.

Silo Pharma, Inc., a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, has advanced the formulation development for its therapeutic drug, SPC-15. The liquid nasal formulation will be used in SPC-15’s novel protocol intended for treatment and prevention of anxiety, PTSD, and other stress related disorders. The formulation development was in accordance with the company’s sponsored research agreement and option with Columbia Univ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters